Amphastar Pharmaceuticals, Inc. (AMPH)

Market Cap	1.17B
Revenue (ttm)	730.66M
Net Income (ttm)	141.63M
Shares Out	47.50M
EPS (ttm)	2.77
PE Ratio	8.91
Forward PE	7.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	751,566
Open	24.22
Previous Close	24.43
Day's Range	23.91 - 25.34
52-Week Range	22.64 - 53.96
Beta	0.78
Analysts	Buy
Price Target	40.67 (+64.99%)
Earnings Date	May 7, 2025

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emer...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2014
• Employees: 2,028
• Stock Exchange: NASDAQ
• Ticker Symbol: AMPH
• Website: https://www.amphastar.com

Financial Performance

In 2024, Amphastar Pharmaceuticals's revenue was $731.97 million, an increase of 13.59% compared to the previous year's $644.40 million. Earnings were $159.52 million, an increase of 15.98%.

Analyst Forecast

According to 4 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is $40.67, which is an increase of 64.99% from the latest price.

Price Target

$40.67

(64.99% upside)

Analyst Consensus: Buy